In mid-2009, Cougar’s tender offer expired (more than 20 billion shares or 95 percent of Cougar stock were tendered) and in May 2009, Johnson & Johnson acquired Cougar Biotechnology Inc. for about $893 million or $43 per share. This merger has recently been completed following large investments by Lindsay Rosenwald, MD, of Paramount BioSciences. Although [...]
Dr. Lindsay A Rosenwald, coordinates work with that group of companies which is mostly concerning investment banking, asset supervision, plus direct investing and venture capital in the life-science and biotechnological business. The organization uses a mixture of national and also foreign hedge funds along with private equity for the purpose of managing their investor assets. [...]
When looking at the pharmaceutical development industry, there is one company who shows a more significant impact and rate of success than any other company of its size. That company, is likely as successful as it is because of the unique structure devised by founder Lindsay Rosenwald. When the company was founded in 1991, it [...]